Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 2.97
INSM's Cash-to-Debt is ranked lower than
67% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. INSM: 2.97 )
Ranked among companies with meaningful Cash-to-Debt only.
INSM' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.14  Med: 37.33 Max: No Debt
Current: 2.97
Piotroski F-Score: 2
Altman Z-Score: 0.98
Beneish M-Score: -4.26
WACC vs ROIC
15.31%
-334.56%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE % -72.42
INSM's ROE % is ranked lower than
70% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -38.58 vs. INSM: -72.42 )
Ranked among companies with meaningful ROE % only.
INSM' s ROE % Range Over the Past 10 Years
Min: -361.62  Med: -44.96 Max: 195.47
Current: -72.42
-361.62
195.47
ROA % -58.81
INSM's ROA % is ranked lower than
70% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -33.01 vs. INSM: -58.81 )
Ranked among companies with meaningful ROA % only.
INSM' s ROA % Range Over the Past 10 Years
Min: -129.17  Med: -37.18 Max: 180.06
Current: -58.81
-129.17
180.06
ROC (Joel Greenblatt) % -1833.95
INSM's ROC (Joel Greenblatt) % is ranked lower than
68% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -496.85 vs. INSM: -1833.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
INSM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -720550  Med: -2254.29 Max: -1133.76
Current: -1833.95
-720550
-1133.76
3-Year Revenue Growth Rate -100.00
INSM's 3-Year Revenue Growth Rate is ranked lower than
94% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. INSM: -100.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
INSM' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -14.3 Max: 481.9
Current: -100
0
481.9
3-Year EBITDA Growth Rate 21.10
INSM's 3-Year EBITDA Growth Rate is ranked higher than
71% of the 506 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. INSM: 21.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
INSM' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -59.4  Med: -15.9 Max: 49.2
Current: 21.1
-59.4
49.2
3-Year EPS without NRI Growth Rate 21.20
INSM's 3-Year EPS without NRI Growth Rate is ranked higher than
75% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. INSM: 21.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
INSM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -59.5  Med: -14.6 Max: 48.4
Current: 21.2
-59.5
48.4
GuruFocus has detected 3 Warning Signs with Insmed Inc $INSM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» INSM's 10-Y Financials

Financials (Next Earnings Date: 2017-05-23 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

INSM Guru Trades in Q1 2016

Paul Tudor Jones 21,553 sh (New)
Jim Simons 183,787 sh (New)
John Paulson 205,200 sh (+24.21%)
» More
Q2 2016

INSM Guru Trades in Q2 2016

Steven Cohen 201,354 sh (New)
Paul Tudor Jones 28,163 sh (+30.67%)
John Paulson 205,200 sh (unchged)
Jim Simons 149,300 sh (-18.76%)
» More
Q3 2016

INSM Guru Trades in Q3 2016

Jim Simons 197,700 sh (+32.42%)
John Paulson 205,200 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones 23,036 sh (-18.20%)
» More
Q4 2016

INSM Guru Trades in Q4 2016

John Paulson 205,200 sh (unchged)
Paul Tudor Jones 22,887 sh (-0.65%)
Jim Simons 120,500 sh (-39.05%)
» More
» Details

Insider Trades

Latest Guru Trades with INSM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:EPZM, OTCPK:BPMUF, NAS:FOLD, NAS:EDIT, OTCPK:PFSCF, NAS:XLRN, NAS:CLCD, NAS:AMRN, NAS:CORT, NAS:XNCR, OTCPK:GNFTF, NAS:FPRX, NAS:AIMT, NAS:ALDR, NAS:CLLS, NAS:ZIOP, NAS:AKAO, NAS:LOXO, NAS:CRSP, NAS:RGEN » details
Traded in other countries:IM8N.Germany,
Insmed Inc is a biopharmaceutical company engaged in developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. Its products candidates includes ARIKAYCE.

Insmed Inc is a global biotechnology company that is focused on developing novel therapies for rare diseases. The company works to develop and commercialize therapies that focus primarily on lung diseases. Insmed is focused broadly on rare disease therapeutics and prioritizing its current therapeutic focus in the fields of pulmonology and infectious disease. The company's strategy includes licensing its patents and pending patent applications. The company's primary businesses are within the U.S., Europe, and Canada, while also maintaining operations in other international markets as well.

Ratios

vs
industry
vs
history
PB Ratio 6.25
INSM's PB Ratio is ranked lower than
71% of the 975 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. INSM: 6.25 )
Ranked among companies with meaningful PB Ratio only.
INSM' s PB Ratio Range Over the Past 10 Years
Min: 0.45  Med: 3.7 Max: 105
Current: 6.25
0.45
105
Current Ratio 6.02
INSM's Current Ratio is ranked higher than
64% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. INSM: 6.02 )
Ranked among companies with meaningful Current Ratio only.
INSM' s Current Ratio Range Over the Past 10 Years
Min: 0.53  Med: 6.54 Max: 44.81
Current: 6.02
0.53
44.81
Quick Ratio 6.02
INSM's Quick Ratio is ranked higher than
66% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. INSM: 6.02 )
Ranked among companies with meaningful Quick Ratio only.
INSM' s Quick Ratio Range Over the Past 10 Years
Min: 0.53  Med: 6.54 Max: 44.81
Current: 6.02
0.53
44.81

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -16.50
INSM's 3-Year Average Share Buyback Ratio is ranked lower than
64% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. INSM: -16.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
INSM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -119  Med: -26.1 Max: -5.4
Current: -16.5
-119
-5.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 12.23
INSM's Price-to-Net-Cash is ranked lower than
73% of the 652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.34 vs. INSM: 12.23 )
Ranked among companies with meaningful Price-to-Net-Cash only.
INSM' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.66  Med: 4.56 Max: 28.56
Current: 12.23
0.66
28.56
Price-to-Net-Current-Asset-Value 11.42
INSM's Price-to-Net-Current-Asset-Value is ranked lower than
76% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. INSM: 11.42 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
INSM' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.64  Med: 4.49 Max: 25.28
Current: 11.42
0.64
25.28
Price-to-Tangible-Book 10.03
INSM's Price-to-Tangible-Book is ranked lower than
80% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. INSM: 10.03 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
INSM' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.53  Med: 4.39 Max: 13.65
Current: 10.03
0.53
13.65
Earnings Yield (Greenblatt) % -20.04
INSM's Earnings Yield (Greenblatt) % is ranked lower than
66% of the 1109 Companies
in the Global Biotechnology industry.

( Industry Median: -10.11 vs. INSM: -20.04 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
INSM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -20.83  Med: 28.75 Max: 48928.8
Current: -20.04
-20.83
48928.8

More Statistics

EPS (TTM) $ -2.85
Beta1.74
Short Percentage of Float10.44%
52-Week Range $9.02 - 17.32
Shares Outstanding (Mil)62.02

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 86 191
EPS ($) -1.78 -0.89 0.38
EPS without NRI ($) -1.78 -0.89 0.38
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)